U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07760077) titled 'Phase I Study of QLS1510 Tablets in Healthy Participants' on Aug. 04.
Brief Summary: This is a Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QLS1510 in Healthy participants
Study Start Date: Aug. 30
Study Type: INTERVENTIONAL
Condition:
Inflammatory Bowel Disease (IBD)
Intervention:
DRUG: QLS1510 Tablets
Oral (swallow)
DRUG: QLS1510 placebo Tablets
Oral (swallow)
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shanghai Qilu Pharmaceutical Research and Development Center LTD
Published by HT Digi...